US Stock MarketDetailed Quotes
INZY Inozyme Pharma
- 2.710
- -0.010-0.37%
Close Nov 29 13:00 ET
- 2.830
- +0.120+4.43%
Post 15:20 ET
174.09MMarket Cap-1748P/E (TTM)
2.800High2.680Low364.84KVolume2.760Open2.720Pre Close993.16KTurnover1.00%Turnover RatioLossP/E (Static)64.24MShares7.79552wk High2.10P/B99.09MFloat Cap2.56052wk Low--Dividend TTM36.56MShs Float31.650Historical High--Div YieldTTM4.41%Amplitude0.991Historical Low2.722Avg Price1Lot Size
Inozyme Pharma Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -30.00%-24.53M | -52.16%-23.66M | -38.04%-24.53M | -22.36%-70.68M | -28.38%-18.49M | -30.00%-18.87M | -5.86%-15.55M | -25.51%-17.77M | -19.95%-57.76M | -7.11%-14.4M |
| Net income from continuing operations | -47.67%-24.57M | -73.48%-27.03M | -34.15%-23.35M | -6.13%-71.17M | -16.18%-21.54M | -1.62%-16.64M | -2.11%-15.58M | -3.08%-17.4M | -18.43%-67.06M | 1.12%-18.54M |
| Operating gains losses | ---- | ---- | ---- | 17.65%20K | ---- | ---- | ---- | ---- | --17K | --13K |
| Depreciation and amortization | -6.25%195K | -10.05%188K | -12.08%182K | 11.96%833K | 5.56%209K | 10.05%208K | 16.76%209K | 16.29%207K | 10.39%744K | 8.79%198K |
| Other non cash items | 45.05%454K | 56.79%439K | 101.52%397K | 113.69%1.12M | 85.56%334K | 128.47%313K | 164.15%280K | 91.26%197K | 39.15%526K | 81.82%180K |
| Change In working capital | 34.67%-1.92M | 327.26%2.16M | 36.73%-1.34M | -253.18%-3.08M | 19.10%2.93M | -1,751.12%-2.94M | 31.61%-950K | -376.14%-2.12M | 2,267.06%2.01M | -17.67%2.46M |
| -Change in prepaid assets | 69.38%-890K | -317.24%-726K | 283.17%1.18M | -421.71%-2.02M | -20.49%753K | -31.78%-2.91M | -132.10%-174K | -6.36%309K | 20.21%-387K | 127.64%947K |
| -Change in payables and accrued expense | -563.01%-801K | 689.02%3.11M | -7.06%-2.3M | -104.09%-123K | 51.37%2.38M | -93.20%173K | 69.39%-528K | -450.49%-2.15M | 151.42%3.01M | -42.43%1.58M |
| -Change in other current liabilities | -11.71%-229K | 9.27%-225K | 20.00%-220K | -54.61%-940K | -221.21%-212K | -11.41%-205K | -37.02%-248K | -55.37%-275K | 2.88%-608K | 60.95%-66K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -30.00%-24.53M | -52.16%-23.66M | -38.04%-24.53M | -22.36%-70.68M | -28.38%-18.49M | -30.00%-18.87M | -5.86%-15.55M | -25.51%-17.77M | -19.95%-57.76M | -7.11%-14.4M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 152.33%23.35M | 209.12%17.82M | -24.50%10.39M | -892.89%-53.65M | -301.06%-6.47M | -440.33%-44.62M | 28.78%-16.33M | -38.99%13.77M | -112.63%-5.4M | -66.08%3.22M |
| Net PPE purchase and sale | -85.71%-13K | --0 | 81.71%-32K | 27.32%-298K | -128.26%-105K | 95.24%-7K | 94.50%-11K | -929.41%-175K | -3.27%-410K | -15.00%-46K |
| Net investment purchase and sale | 152.37%23.36M | 209.19%17.82M | -25.21%10.43M | -968.46%-53.35M | -295.01%-6.37M | -450.04%-44.61M | 28.21%-16.32M | -38.26%13.94M | -111.56%-4.99M | -65.74%3.26M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 152.33%23.35M | 209.12%17.82M | -24.50%10.39M | -892.89%-53.65M | -301.06%-6.47M | -440.33%-44.62M | 28.78%-16.33M | -38.99%13.77M | -112.63%-5.4M | -66.08%3.22M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -84.91%10.52M | -98.06%458K | -99.21%159K | 73.06%125.97M | 12.52M | 1,553.97%69.72M | -65.40%23.64M | 8,273.33%20.1M | 11,852.05%72.79M | 0 |
| Net issuance payments of debt | --0 | --0 | --0 | 887.65%40M | --12.5M | --0 | --7.5M | --20M | --4.05M | --0 |
| Net common stock issuance | -84.99%10.44M | ---- | ---- | 52.57%85.65M | ---2K | 165,723.81%69.56M | ---- | ---- | --56.14M | --0 |
| Proceeds from stock option exercised by employees | -45.75%83K | 732.73%458K | 65.63%159K | -97.44%322K | --18K | -26.09%153K | -99.55%55K | -60.00%96K | 1,969.13%12.6M | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -84.91%10.52M | -98.06%458K | -99.21%159K | 73.06%125.97M | --12.52M | 1,553.97%69.72M | -65.40%23.64M | 8,273.33%20.1M | 11,852.05%72.79M | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -62.23%15.54M | -57.61%20.93M | 4.90%34.9M | 40.55%33.27M | 6.32%47.21M | -34.65%41.16M | 52.89%49.38M | 40.55%33.27M | -16.64%23.67M | 60.96%44.4M |
| Current changes in cash | 49.92%9.34M | 34.60%-5.38M | -186.89%-13.98M | -82.88%1.65M | -11.26%-12.44M | 133.58%6.23M | -126.80%-8.23M | 86.18%16.09M | 302.70%9.62M | -183.38%-11.18M |
| Effect of exchange rate changes | 99.45%-1K | -109.09%-1K | -47.37%10K | 28.00%-18K | 152.83%134K | -810.00%-182K | 125.58%11K | 226.67%19K | -204.17%-25K | 60.61%53K |
| End cash Position | -47.28%24.89M | -62.23%15.54M | -57.61%20.93M | 4.90%34.9M | 4.90%34.9M | 6.32%47.21M | -34.65%41.16M | 52.89%49.38M | 40.55%33.27M | 40.55%33.27M |
| Free cash flow | -30.02%-24.54M | -52.05%-23.66M | -36.88%-24.57M | -22.01%-70.97M | -28.70%-18.59M | -28.74%-18.88M | -4.51%-15.56M | -26.59%-17.95M | -19.82%-58.17M | -7.13%-14.45M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data